Study summary

Osimertinib after chemoradiation kept stage III lung cancer in check for years

LAURA trial (osimertinib after chemoradiation) · 216 people, phase 3 · Published August 2024, New England Journal of Medicine

39.1months without progression, vs 5.6 with placebo

What was tested

Osimertinib against placebo in people with unresectable stage III EGFR-mutated lung cancer whose disease had not grown after chemotherapy and radiation.

What they found

What it means

Made osimertinib a standard follow-on treatment after chemoradiation for stage III disease.

N Engl J Med, via PubMed ↗ Trial record NCT03521154 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.